

Strides Arcolab gets import alert from USFDA

BS REPORTER

Bangalore, 10 October

Strides Arcolab, a Bangalore-based mid-size publicly-held pharmaceutical company, has received a shocker from the US Food and Drug Administration (USFDA) in the form of an import alert on one of its skin-care products. The company has, however, said the product is not meant for the US market and it has approval to supply to a customer only in Africa.

"The products mentioned in the Import Alert by USFDA are manufactured by our Italian subsidiary Beltapharm for an African customer for over five years and we are working with the USFDA and the African customer, on the circumstances on how these products reached the US market. Strides further wishes to clarify that it has no role in the distribution of any of these products in the US territory," Strides said in a statement.

The company added that its Italian subsidiary has only one Abbreviated New Drug Application (ANDA)-approved product, Imiquimod cream, for the US market and this product has been recently launched and is freely available. Besides Strides' instance of being under the USFDA scanner, large-cap pharma companies from India including Ranbaxy and Wockhardt have also been under severe pressure over various issues with the USFDA.

Company